- Home
- NUTR vs ADVM Comparison
NUTR vs ADVM Comparison
Compare NUTR & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUTR
- ADVM
- Stock Information
- Founded
- NUTR 2013
- ADVM 2006
- Country
- NUTR Indonesia
- ADVM United States
- Employees
- NUTR N/A
- ADVM N/A
- Industry
- NUTR
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NUTR
- ADVM Health Care
- Exchange
- NUTR Nasdaq
- ADVM Nasdaq
- Market Cap
- NUTR 94.1M
- ADVM 94.6M
- IPO Year
- NUTR 2025
- ADVM 2014
- Fundamental
- Price
- NUTR $9.30
- ADVM $5.39
- Analyst Decision
- NUTR
- ADVM Strong Buy
- Analyst Count
- NUTR 0
- ADVM 4
- Target Price
- NUTR N/A
- ADVM $19.75
- AVG Volume (30 Days)
- NUTR 2.7M
- ADVM 727.0K
- Earning Date
- NUTR 11-02-2025
- ADVM 11-03-2025
- Dividend Yield
- NUTR N/A
- ADVM N/A
- EPS Growth
- NUTR N/A
- ADVM N/A
- EPS
- NUTR 0.00
- ADVM N/A
- Revenue
- NUTR $1,743,679.00
- ADVM $1,000,000.00
- Revenue This Year
- NUTR N/A
- ADVM $1,836.70
- Revenue Next Year
- NUTR N/A
- ADVM N/A
- P/E Ratio
- NUTR $3,995.74
- ADVM N/A
- Revenue Growth
- NUTR N/A
- ADVM N/A
- 52 Week Low
- NUTR $3.40
- ADVM $1.78
- 52 Week High
- NUTR $9.50
- ADVM $8.56
- Technical
- Relative Strength Index (RSI)
- NUTR N/A
- ADVM 79.42
- Support Level
- NUTR N/A
- ADVM $4.01
- Resistance Level
- NUTR N/A
- ADVM $5.75
- Average True Range (ATR)
- NUTR 0.00
- ADVM 0.59
- MACD
- NUTR 0.00
- ADVM 0.16
- Stochastic Oscillator
- NUTR 0.00
- ADVM 87.50
About NUTR Nusatrip Incorporated Common Stock
NusaTrip Inc operates as an Online Travel Agent offering Hotel & Flight Tickets, Domestic and International. The Company currently operates in a single reportable operating segment with five different services: Ticketing, Online advertisement, Hotel reservation, Hotel technology platform software, and Ancillary. The group earns revenue through commissions, service fees, and advertising partnerships.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.